Researchers at the NCI-designated Sylvester Comprehensive Cancer Center, working within several departments at the University of Miami Miller School of Medicine, have identified another critical component of the AML1-ETO multi-protein complex that could point the way to more effective therapies for acute myeloid leukemia (AML).
A study looking at PARP inhibition in diffuse large B cell lymphoma opens the door to a new way to treat this common type of cancer, according to study author Izidore S. Lossos, M.D., endowed director of the Lymphoma Program at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and head of the Hematological Malignancies Site Disease Group.
Researchers have struggled with the challenge of getting oral medications past the treacherous environment of the gut intact and into the bloodstream where they can be most effective. But now Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine researchers report success in accomplishing this breakthrough using nanotechnology.
Two recent studies by Sylvester Comprehensive Cancer Center researchers are the first to suggest that immunotherapy plays a key role in treating sarcomas, namely angiosarcoma and alveolar soft-part sarcoma. The findings could change the treatment paradigm for sarcoma types that have few if any treatment options.